
The systematic review explores the burden experienced by individuals with generalized myasthenia gravis (gMG), a rare autoimmune disease causing muscle weakness. Examining 39 publications, it encompasses diverse patient-reported outcome measures (PROMs) and qualitative assessments. The findings indicate significantly impaired quality of life (QoL) in gMG compared to healthy individuals or those with ocular MG (oMG), with QoL deteriorating as MG severity increases. The review underscores the importance of prioritizing patient QoL in treatment planning, advocating for further standardized studies to enhance understanding and management.
Like
Save
Share